Key Highlights
- 10.88% was the intraday decline in Novavax (NASDAQ:NVAX) on October 16, 2026, to USD 11.43, with 27.92% of float sold short and 8.1 days to cover, per published market data. It follows a 20.08% rally on October 5.
- 8.18% was the decline in Recursion (NASDAQ:RXRX) to USD 3.82 after it priced a USD 200 million offering of 61,540,000 Class A shares at USD 3.25 on October 15, 2026, per the 8-K. Short interest is 29.50% of float.
- 9.96% was the decline in SELLAS Life Sciences (NASDAQ:SLS) in the table to USD 10.21, with 27.30% of float short and 9.4 days to cover. An earlier intraday reading showed USD 9.97, down 12.04%, so the figures conflict.
- 4.12% was the decline in CleanSpark (NASDAQ:CLSK) to USD 8.96, with 29.71% of float short and 4.4 days to cover. The stock is 27.1% below its October 6 close of USD 12.29, own arithmetic.
Novavax (NASDAQ:NVAX)
The market traded outbreak headlines, though the company has no plague vaccine. Novavax (NASDAQ:NVAX) rose 20.08% on October 5, 2026, to USD 12.56 as shorts covered after a Vaxcyte late-stage pneumonia vaccine result and unconfirmed reports of a suspected plague case in Russia. The shares fell 12% on October 6 when the World Health Organization said tested contacts showed no plague. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026 for the 10.88% decline, which reads as a continued unwinding. FINRA data for September 30 show 46,046,946 shares short, worth USD 526 million at the quote (own arithmetic). Second quarter revenue fell 76% to USD 56.7 million because the prior year held USD 202 million of milestone revenue. What separates it from the other three: the largest decline and a sentiment, not company, driver. So what: cash of USD 723.9 million at June 30 against a stockholders' deficit of USD 190.7 million leaves the equity dependent on guided revenue of USD 235 million to USD 275 million. Third quarter results are expected in early November, unconfirmed.
Recursion (NASDAQ:RXRX)
An offering priced on good news is a different event from a decline on bad news. Recursion (NASDAQ:RXRX) reported REC-4881 data and a Sanofi option on October 15, 2026, then priced stock at USD 3.25, which is 21.9% below the implied October 15 close of USD 4.16 (own arithmetic). The 61.54 million new shares add 11.5% to the 535.34 million outstanding (own arithmetic). Preliminary cash at September 30 was USD 561 million, with runway guided into 2029 including the offering. The data showed 87% of evaluable patients (13 of 15) with polyp burden reductions, but the study is small and 4 of 26 patients had Grade 3 treatment-related events. FINRA data for September 30 show 157,938,412 shares short, worth USD 603 million at the quote (own arithmetic). What separates it from the other three: the decline has an identified cause, new supply. So what: the offering weakens the financing argument for shorts and caps rallies. More REC-4881 data are due on November 2, 2026, and earnings are estimated for November 4.
SELLAS Life Sciences (NASDAQ:SLS)
A binary readout is close, and the quote is moving without news. SELLAS Life Sciences (NASDAQ:SLS) shows USD 10.21, down 9.96%, in the table, against USD 9.97, down 12.04%, in an earlier intraday reading, and this article uses the table figure for ranking. No company-specific catalyst was identified through October 16, 2026. The REGAL Phase 3 trial of galinpepimut-S in acute myeloid leukemia was last reported at 78 of 80 events, and the 80th event triggers database lock and unblinding. Table short interest of 27.30% and 9.4 days to cover compare with 32.33% in a mid-July reading. On the USD 2.06 billion market capitalisation and USD 10.21, up to 55.1 million shares are short, worth up to USD 562 million, an upper bound because float is lower (own arithmetic). Cash was USD 138.3 million at June 30, 2026, which is 43 months at the second quarter net loss rate (own arithmetic). What separates it from the other three: the sharpest binary risk. So what: a USD 150 million at-the-market program was reported, with terms not reviewed, and the 80th event has no confirmed date.
CleanSpark (NASDAQ:CLSK)
The smallest decline sits on the heaviest debt. CleanSpark (NASDAQ:CLSK) fell 4.12% to USD 8.96, for a USD 2.30 billion market capitalisation, and no company-specific catalyst was identified for the session. The structural pressure is financing: USD 2.276 billion of 7.875% notes priced on September 25, 2026 imply USD 179 million of annual interest (own arithmetic). Bitcoin (BTC) fell below USD 81,000 on October 8, 36.8% under the USD 128,198 record of October 6, 2025 (own arithmetic). The September 15 short position of 78.58 million shares is worth USD 704 million at the quote (own arithmetic), and part may be hedging by holders of the USD 1.15 billion zero-coupon convertibles, an unconfirmed inference. What separates it from the other three: the shorts are paid by a falling bitcoin price and leverage, not by a clinical or offering event. So what: a signed Sandersville lease or a bitcoin rebound would be the covering trigger. Fiscal fourth quarter results are estimated for November 24, 2026.
Where Things Stand
Novavax (NASDAQ:NVAX) is under the most pressure, with a decline of 10.88%, because a rally built on plague headlines has unwound. SELLAS Life Sciences (NASDAQ:SLS) follows at 9.96% in the table, or 12.04% on the earlier reading, which would rank it first. Recursion (NASDAQ:RXRX) is down 8.18%. CleanSpark (NASDAQ:CLSK) is down 4.12%. By short interest CLSK ranks first at 29.71%, then RXRX at 29.50%, NVAX at 27.92% and SLS at 27.30%. Only RXRX has a dated offering as its cause. Falling prices let shorts hold profit and do not signal covering.






Please wait processing your request...